KV Pharmaceutical Company has received approval from the United States Food and Drug Administration (FDA) to market Clindesse (clindamycin phosphate) Vaginal Cream, 2%, a single-dose prescription cream therapy indicated to treat bacterial vaginosis (BV).
Clindesse, which utilizes KV's proprietary VagiSite bioadhesive drug delivery technology, is the first approved single-dose therapy for patients with bacterial vaginosis the most common form of vaginitis. The one-dose product was demonstrated in clinical trials to effectively treat BV and its symptoms with results equivalent to 7 days of Cleocin vaginal cream, the company said in a release.
Marc S. Hermelin, VC and CEO of KV said, "As the only single-dose therapy approved for convenient and effective treatment of BV, we believe Clindesse's convenience will be compelling to both physicians and their patients. In clinical trials supporting the product's approval, more than 95 per cent of patients taking Clindesse complied with the treatment regimen, as compared with 65 per cent compliance with the 7-day prescription cream comparator. The arrival of Clindesse further underscores our Ther-Rx subsidiary's growing prominence in the important vaginal anti-infective therapeutic segment of the women's health market. Ther-Rx anticipates the launch of Clindesse in January 2005."
Bacterial vaginosis, is believed to represent nearly half of all vulvovaginal infections. In fact, the intravaginal BV product segment alone has an estimated US market size of $138 million for the twelve months ending October 2004, according to IMS NSP.